Haematologica (Jun 2014)
Clinically relevant doses of FLT3-kinase inhibitors quizartinib and midostaurin do not impair T-cell reactivity and function
- Denise Wolleschak,
- Thomas S. Mack,
- Florian Perner,
- Stephanie Frey,
- Tina M. Schnöder,
- Marie-Christine Wagner,
- Christine Höding,
- Marina C. Pils,
- Andreas Parkner,
- Stefanie Kliche,
- Burkhart Schraven,
- Katrin Hebel,
- Monika Brunner-Weinzierl,
- Satish Ranjan,
- Berend Isermann,
- Daniel B. Lipka,
- Thomas Fischer,
- Florian H. Heidel
Affiliations
- Denise Wolleschak
- Department of Hematology and Oncology, Center of Internal Medicine, Otto-von-Guericke University Medical Center, Magdeburg, Germany
- Thomas S. Mack
- Department of Hematology and Oncology, Center of Internal Medicine, Otto-von-Guericke University Medical Center, Magdeburg, Germany
- Florian Perner
- Department of Hematology and Oncology, Center of Internal Medicine, Otto-von-Guericke University Medical Center, Magdeburg, Germany
- Stephanie Frey
- Department of Hematology and Oncology, Center of Internal Medicine, Otto-von-Guericke University Medical Center, Magdeburg, Germany
- Tina M. Schnöder
- Department of Hematology and Oncology, Center of Internal Medicine, Otto-von-Guericke University Medical Center, Magdeburg, Germany
- Marie-Christine Wagner
- Department of Hematology and Oncology, Center of Internal Medicine, Otto-von-Guericke University Medical Center, Magdeburg, Germany
- Christine Höding
- Department of Hematology and Oncology, Center of Internal Medicine, Otto-von-Guericke University Medical Center, Magdeburg, Germany
- Marina C. Pils
- Mousepathology, Animal Experimental Unit, Helmholtz-Center for Infection Research, Braunschweig, Germany
- Andreas Parkner
- Department of Transfusion Medicine, Otto-von-Guericke University Medical Center, Magdeburg, Germany
- Stefanie Kliche
- Institute of Molecular and Clinical Immunology, Otto-von-Guericke University Medical Center, Magdeburg, Germany
- Burkhart Schraven
- Institute of Molecular and Clinical Immunology, Otto-von-Guericke University Medical Center, Magdeburg, Germany;Department of Immune Control, Helmholtz Center for Infection Research, Braunschwei, Germany
- Katrin Hebel
- Department of Experimental Pediatrics, Otto-von-Guericke University Medical Center, Magdeburg, Germany
- Monika Brunner-Weinzierl
- Department of Experimental Pediatrics, Otto-von-Guericke University Medical Center, Magdeburg, Germany
- Satish Ranjan
- Institute of Clinical Chemistry and Pathobiochemistry, Otto-von-Guericke University Medical Center, Magdeburg, Germany
- Berend Isermann
- Institute of Clinical Chemistry and Pathobiochemistry, Otto-von-Guericke University Medical Center, Magdeburg, Germany
- Daniel B. Lipka
- Department of Hematology and Oncology, Center of Internal Medicine, Otto-von-Guericke University Medical Center, Magdeburg, Germany;German Cancer Research Center (DKFZ), Division of Epigenomics and Cancer Risk Factors, Heidelberg, Germany
- Thomas Fischer
- Department of Hematology and Oncology, Center of Internal Medicine, Otto-von-Guericke University Medical Center, Magdeburg, Germany
- Florian H. Heidel
- Department of Hematology and Oncology, Center of Internal Medicine, Otto-von-Guericke University Medical Center, Magdeburg, Germany
- DOI
- https://doi.org/10.3324/haematol.2014.104331
- Journal volume & issue
-
Vol. 99,
no. 6
Abstract
No abstracts available.